CODX Stock Risk & Deep Value Analysis

Co-Diagnostics Inc

Healthcare • Medical Devices

DVR Score

3.8

out of 10

Risk Trap

The Bottom Line on CODX

We analyzed Co-Diagnostics Inc using our deep value framework. Sign in to see our full verdict and DVR Score.

We ran CODX through our deep value framework — analyzing financial health, distress signals, competitive moat, and risk factors. Here's what we found.

Updated Apr 16, 2026•Run Fresh Analysis →•

Get notified when CODX moves

Same alert types as Telegram — presets or custom thresholds in your 🔔 feed.

📈CODX Performance Overview3yr weekly

📊

Unlock CODX Performance Chart

See 3 years of price history, quarterly revenue trends, and DVR score changes

Weekly adjusted close · Quarterly revenue & EPS · DVR score history

CODX Quality Rating

5.0

Growth

1.0

Profitability

4.0

Health

2.0

Capital allocation

4.0

Momentum

CODX Stock Risk Analysis

Overall Risk

Aggressive

Financial Risk

High

Market Risk

High

About Co-Diagnostics Inc (CODX)

Sector

Healthcare

Industry

Medical Devices

Market Cap Category

small

Market Cap

$5.12M

CODX Deep Value Analysis

Co-Diagnostics (CODX) remains a highly speculative, high-risk investment, now facing severe financial headwinds. The company reported a significant 84.6% YoY revenue decline in FY2025 and a 60% reduction in cash, indicating rapid cash burn. Despite these challenges, CODX continues its strategic pivot, showcasing its Co-Dx PCR platform and expanding international relationships, which aligns with previous operational goals. The balance sheet still shows a strong current ratio, but the operational runway is shortening. The path to 10x growth is entirely dependent on an aggressive and successful commercialization of new products and market penetration, making it an extremely high-risk, high-reward proposition with substantial financial risks. Score Change Explanation: The score has been adjusted downwards from 4.6/10 to 3.8/10 to reflect the materially negative financial results reported for Q4/Full Year 2025 (released March 31, 2026), which was after the previous analysis date. Specifically, the company reported an alarming 84.6% YoY revenue decline and a significant 60% reduction in cash and marketable securities, indicating substantial cash burn. While strategic operational execution continues (e.g., ESCMID conference, CoSara JV expansion), the severe financial deterioration raises immediate concerns about the company's operational runway and the time needed for its strategic pivot to yield tangible financial results, increasing the overall risk profile.

CODX Research Sources

Research sources

No external source links for this analysis yet. Run a fresh analysis to capture SEC filings and financial news articles we used.

For educational context only. Not financial advice.

CODX Red Flags & Warning Signs

⚠
Failure of Co-Dx PCR platform to gain market traction or secure significant orders
⚠
Further accelerated cash burn requiring highly dilutive capital raises
⚠
Intensified competition in molecular diagnostics leading to price compression
⚠
Negative regulatory developments or delays in product approvals

Unlock CODX Red Flags & Risk Warnings

Premium members see every risk event we found.

📈

Unlock the full report

Create a free account to see the DVR score, risk flags, and AI analysis.

🔥 New Member Exclusive

Unlock everything for $47/yr

$79/yrSave 41%

✓ Catalysts, bull case, moat & red flags
✓ Unlimited stock analyses + alerts
✓ Full database, search & portfolio (50 stocks)

Get Premium — $47/yr

7-day money back · Cancel anytime

CODX Financial Health Metrics

Market Cap

$5.12M

Profit Margin

-7533.61%

Beta (Volatility)

1.30

Earnings Per Share

$-32.39

CODX Competitive Moat Analysis

Moat Rating

None

Moat Trend

Eroding (The company's historical revenue streams are collapsing, and while they are trying to build a new moat around their Co-Dx platform, it is not yet proven or generating meaningful revenue.)

Moat Sources

1 Identified

Intangible Assets/IP (related to Co-Dx PCR platform)

Highly uncertain. The durability of any potential moat is dependent on the unique efficacy and cost-effectiveness of the Co-Dx PCR platform, its successful regulatory approval and market adoption, and its ability to withstand competition from larger, well-funded diagnostic giants with established distribution networks.

CODX Competitive Moat Analysis

Premium unlocks moat rating, sources & durability.

CODX Catalysts & Growth Drivers

Near-Term (0-6 months)

•ESCMID 2026 Conference (April 17-21, 2026) - potential for international commercial relationship announcements
•Q1 2026 Earnings (Estimated mid-May 2026) - focus on commentary regarding commercialization progress

Medium-Term (6-18 months)

•First substantial revenue contributions from Co-Dx PCR platform commercialization (Q3/Q4 2026)
•Major partnership or distribution agreement for TB diagnostics in South Asia through CoSara JV
•Further regulatory approvals or expanded indications for Co-Dx PCR platform

Long-Term (18+ months)

•Establishment as a niche leader in specific molecular diagnostics segments (e.g., TB testing)
•Broad adoption of Co-Dx PCR as a preferred platform in emerging markets
•Attainment of sustainable profitability and positive free cash flow

Catalysts & Growth Drivers

CODX Bull Case: What Could Go Right

✓
Consistent quarter-over-quarter revenue growth demonstrating traction of new products/markets
✓
Material reduction in quarterly cash burn and progress towards positive operating cash flow
✓
Announcements of significant commercial partnerships or large-scale adoption contracts
✓
Positive regulatory updates or expanded product claims for the Co-Dx PCR platform

Bull Case Analysis

📊 Explore More Stock Analysis

Get comprehensive Deep Value Reports for thousands of stocks. Research risk, financial health, and investment potential.

Analyze Any Stock →View Top 100 Deep Value Stocks →

FAQ

What is the DVR Score for Co-Diagnostics Inc (CODX)?

As of April 16, 2026, Co-Diagnostics Inc has a DVR Score of 3.8 out of 10, placing it in the "Risk Trap" category. This score is generated by our AI-powered deep value analysis framework that evaluates growth potential, financial health, competitive moat, and risk factors.

What is the market capitalization of Co-Diagnostics Inc?

Co-Diagnostics Inc's market capitalization is approximately $5.1M. The company operates in the Healthcare sector within the Medical Devices industry.

What ticker symbol does Co-Diagnostics Inc use?

CODX is the ticker symbol for Co-Diagnostics Inc. The company trades on the NCM.

What is the risk level for CODX stock?

Our analysis rates Co-Diagnostics Inc's overall risk as Aggressive. This assessment considers execution risk, market risk, financial risk, competitive risk, and regulatory risk. For a full breakdown, see the risk analysis section above.

Is Co-Diagnostics Inc's revenue growing?

Co-Diagnostics Inc has reported revenue growth of -84.1%. Revenue has been declining, which warrants closer examination.

Is CODX stock profitable?

Co-Diagnostics Inc has a profit margin of -7533.6%. The company is currently unprofitable.

How often is the CODX DVR analysis updated?

Our AI-powered analysis of Co-Diagnostics Inc is refreshed regularly to incorporate the latest financial data, market conditions, and news. The most recent update was on April 16, 2026.

Important Disclaimer – Not Financial Advice

Deep Value Reports is an independent research platform for educational and informational purposes only. We are not financial advisors, investment advisors, or licensed professionals. The analysis, scores, and information provided should not be construed as personalized investment advice, a recommendation to buy or sell any security, or an offer to provide investment advisory services.

All investments involve risk, including the potential loss of principal. Past performance does not guarantee future results. Always conduct your own research and consult with a qualified financial advisor.